The short version of fatty diacid fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The Oxford team analysed the chemical properties of the cephalosporin ring system, opening the door to the production of semisynthetic cephalosporins created through replacing side chains, as had been done with penicillin to create semisynthetic penicillins. "Everybody I have questioned who was involved in the development of cephalosporin C," science writer David Wilson reported, "when asked if one man was responsible for keeping the project going, replied: 'Florey'." Controversy over British firms having to pay royalties to American ones for the use of the deep submergence techniques developed in the United States to produce penicillin when penicillin was seen as a British innovation led to the establishment of the National Research Development Corporation (NRDC) in June 1948. The Oxford team patented their work on cephalosporins and assigned the patents to the NRDC. By 1978, the annual world sales of cephalosporins were worth over £600,000 (equivalent to £3,279,000 in 2025) and the NRDC was reaping £100,000 (equivalent to £546,000 in 2025) a year in royalties. Florey received a 0.5 per cent share in the last two years of his life.
In the late 1990s, evidence began accumulating to suggest that some GPCRs are able to signal without G proteins. The ERK2 mitogen-activated protein kinase, a key signal transduction mediator downstream of receptor activation in many pathways, has been shown to be activated in response to cAMP-mediated receptor activation in the slime mold D. discoideum despite the absence of the associated G protein α- and β-subunits. In mammalian cells, the much-studied β2-adrenoceptor has been demonstrated to activate the ERK2 pathway after arrestin-mediated uncoupling of G-protein-mediated signaling. Therefore, it seems likely that some mechanisms previously believed related purely to receptor desensitisation are actually examples of receptors switching their signaling pathway, rather than simply being switched off. In kidney cells, the bradykinin receptor B2 has been shown to interact directly with a protein tyrosine phosphatase. The presence of a tyrosine-phosphorylated ITIM (immunoreceptor tyrosine-based inhibitory motif) sequence in the B2 receptor is necessary to mediate this interaction and subsequently the antiproliferative effect of bradykinin.
2 UO2 + O2 + 6 CO2−3 → 2 [UO2(CO3)3]4− This equation suggests that the best solvent for the uranyl carbonate processing is a mixture of carbonate with bicarbonate. At high pH, this results in precipitation of diuranate, which is treated with hydrogen in the presence of nickel yielding an insoluble uranium tetracarbonate. Another separation method uses polymeric resins as a polyelectrolyte. Ion exchange processes in the resins result in separation of uranium. Uranium from resins is washed with a solution of ammonium nitrate or nitric acid that yields uranyl nitrate, UO2(NO3)2·6H2O. When heated, it turns into UO3, which is converted to UO2 with hydrogen:
=== A10BD Combinations of oral blood glucose lowering drugs === A10BD01 Phenformin and sulfonylureas A10BD02 Metformin and sulfonylureas A10BD03 Metformin and rosiglitazone A10BD04 Glimepiride and rosiglitazone A10BD05 Metformin and pioglitazone A10BD06 Glimepiride and pioglitazone A10BD07 Metformin and sitagliptin A10BD08 Metformin and vildagliptin A10BD09 Pioglitazone and alogliptin A10BD10 Metformin and saxagliptin A10BD11 Metformin and linagliptin A10BD12 Pioglitazone and sitagliptin A10BD13 Metformin and alogliptin A10BD14 Metformin and repaglinide A10BD15 Metformin and dapagliflozin A10BD16 Metformin and canagliflozin A10BD17 Metformin and acarbose A10BD18 Metformin and gemigliptin A10BD19 Linagliptin and empagliflozin A10BD20 Metformin and empagliflozin A10BD21 Saxagliptin and dapagliflozin A10BD22 Metformin and evogliptin A10BD23 Metformin and ertugliflozin A10BD24 Sitagliptin and ertugliflozin A10BD25 Metformin, saxagliptin and dapagliflozin A10BD26 Metformin and lobeglitazone A10BD27 Metformin, linagliptin and empagliflozin A10BD28 Metformin and teneligliptin A10BD29 Sitagliptin and dapagliflozin A10BD30 Gemigliptin and dapagliflozin A10BD31 Metformin, sitagliptin and dapagliflozin A10BD32 Glimepiride and dapagliflozin A10BD33 Pioglitazone and dapagliflozin A10BD34 Metformin and enavogliflozin
=== Chinese === Chinese soy sauces (Chinese: 醬油; pinyin: jiàng yóu; Jyutping: zoeng3 jau4; Cantonese Yale: jeungyàuh; or alternatively, 豉油; pinyin: chǐyóu; Jyutping: si6jau4; Cantonese Yale: sihyàuh) are primarily made from soybeans, with relatively low amounts of other grains. Chinese soy sauce produced by fermentation can be roughly split into two classes: brewed (direct fermented) or blended (with additives), occupying about 40% and 60% of market share respectively. Sauces can also be classed by fermentation technology (shown above) into Low-Salt Solid-State fermented soy sauce (LSF; 低鹽固態) and High-Salt Liquid-State fermented soy sauce (HLF; 高鹽稀態), occupying about 90% and 10% of market share respectively.
Sources: en.wikipedia.org
== Drawbacks == The drawbacks of the SMB are higher investment cost compared to single column operations, a higher complexity, as well as higher maintenance costs. But these drawbacks are effectively compensated by the better yield and a much lower solvent consumption as well as a much higher productivity compared to simple batch separations. For purifications, in particular the isolation of an intermediate single component or a fraction out of a multicomponent mixture, the SMB is not as ideally suited. Normally, a single SMB will separate only two fractions from each other, but a series or "train" of SMBs can perform multiple cuts and purify one or more products from a multi-component mixture. SMB is not readily suited for solvent gradients. Solvent gradient purification may be preferred for the purification of some biomolecules. A continuous chromatography technique to overcome the two fraction limit and to apply gradients is multicolumn countercurrent solvent gradient purification (MCSGP).
The peak of these incidents occurred in 1980, with new recruit Phil Carman making headlines for head-butting an umpire. The tribunal suspended him for sixteen weeks, and although most people thought this was a fair (or even lenient) sentence, he took his case to the Supreme Court of Victoria, gathering even more unwanted publicity for the club. Despite this, the club had recruited many talented young players in the late 1970s who emerged as club greats. Three of those young players were Simon Madden, Tim Watson and Paul Van Der Haar. Terry Daniher and his brother Neale came via a trade with South Melbourne, and Roger Merrett joined soon afterwards to form the nucleus of what would become the formidable Essendon sides of the 1980s. This raw but talented group of youngsters took Essendon to an elimination final in 1979 under Barry Davis but were again thrashed in an Elimination Final, this time at the hands of Fitzroy. Davis resigned at the end of the 1980 season after missing out on a finals appearance. One of the few highlights for Essendon supporters during this time was when Graham Moss won the 1976 Brownlow Medal; he was the only Bomber to do so in a four-decade span from 1953 to 1993. Even that was bittersweet, as he quit VFL football to move back to his native Western Australia, where Moss finished out his career as a player and coach at Claremont Football Club. In many ways, Moss's career reflects Essendon's mixed fortunes during the decade.
Of the people studied, 66% were cocaine users. After experiencing long-term in-patient treatment, only 22% returned to the use of cocaine. During the 1990s, the Clinton administration commissioned a major cocaine policy study by the RAND Drug Policy Research Center. The report recommended that $3 billion be switched from federal and local law enforcement to treatment, concluding that treatment is the cheapest way to cut drug use, and twenty-three times more effective than the supply-side war on drugs.
Atomic mass (ma or m) is the mass of a single atom. The atomic mass mostly comes from the combined mass of the protons and neutrons in the nucleus, with minor contributions from the electrons and nuclear binding energy. The atomic mass of atoms, ions, or atomic nuclei is slightly less than the sum of the masses of their constituent protons, neutrons, and electrons, due to mass defect (explained by mass–energy equivalence: E = mc2). Atomic mass is often measured in dalton (Da) (a.k.a. unified atomic mass unit (u)). One dalton is equal to +1/12 the mass of a carbon-12 atom in its natural state, given by the atomic mass constant mu = m(12C)/12 = 1 Da, where m(12C) is the atomic mass of carbon-12. Thus, the numerical value of the atomic mass of a nuclide when expressed in daltons is close to its mass number. The relative isotopic mass (see section below) can be obtained by dividing the atomic mass ma of an isotope by the atomic mass constant mu, yielding a dimensionless value. Thus, the atomic mass of a carbon-12 atom m(12C) is 12 Da by definition, but the relative isotopic mass of a carbon-12 atom Ar(12C) is simply 12. The sum of relative isotopic masses of all atoms in a molecule is the relative molecular mass. The atomic mass of an isotope and the relative isotopic mass refers to a certain specific isotope of an element. Because substances are usually not isotopically pure, it is convenient to use the elemental atomic mass which is the average atomic mass of an element, weighted by the abundance of the isotopes.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.